SCHEMBL30765811

SCHEMBL30765811

CCCCOC(=O)Cn1c(N2CCCCC2)ncc(N[C@H](C)c2cnc(-c3ccccc3)o2)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
LMNA P02545 5/20 0.37
ALDH1A1 P00352 3/20 0.37
POLB P06746 2/20 0.37
MAPT P10636 2/20 0.37
TSHR P16473 5/20 0.36
NPSR1 Q6W5P4 3/20 0.36
PPARG P37231 3/20 0.34
MAPK1 P28482 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ADORA1 P30542 1/20 0.34
NPC1 O15118 1/20 0.33
TP53 P04637 1/20 0.33
NFKB1 P19838 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30766001 0.87 AKT1 (0.36) L3MBTL1KMT2AMEN1LMNAALDH1A1
SCHEMBL30765528 0.87 ALDH1A1 (0.36) LMNAALDH1A1TSHRNPSR1KDM4E
SCHEMBL30765621 0.85 GAA (0.42) L3MBTL1GAAKMT2AMEN1LMNA
SCHEMBL30765996 0.84 MAPT (0.41) L3MBTL1GAAKMT2AMEN1LMNA
SCHEMBL30765509 0.81 LMNA (0.43) L3MBTL1GAAKMT2AMEN1LMNA
SCHEMBL30765616 0.79 LMNA (0.37) L3MBTL1GAAKMT2AMEN1LMNA
SCHEMBL30765553 0.76 MAPK1 (0.37) ALDH1A1MAPK1
SCHEMBL30765532 0.73 GAA (0.53) L3MBTL1GAAKMT2AMEN1POLB
SCHEMBL30765514 0.73 ALDH1A1 (0.48) L3MBTL1GAAKMT2AMEN1LMNA
SCHEMBL30765445 0.71 AKT1 (0.37) L3MBTL1KMT2AMEN1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed